Archives

Corley

My current research explores epigenetic and environmental mechanisms of disease in the setting of the immune system with emphasis on the metabolic disease and interactions with infectious and neurological disease.

Somersan-Karakaya

Characterize host and bacterial pathways that are important in Mycobacterium tuberculosis survival in the host and identify targets whose inhibition will render Mtb more susceptible to host defenses.

Rhee

Kyu Rhee

We are interested in the chemical biology of metabolism as a mediator of the host-pathogen interaction. We focus specifically on Mycobacterium tuberculosis and its ability to both asymptomatically infect and cause disease in humans.

Melnick

Ari Melnick

We explore epigenetic mechanisms that are required to drive the humoral immune response, and how disruption of these mechanisms cause malignant transformation into lymphomas.

Ivashkiv

Lionel Ivashkiv

Dr. Ivashkiv’s laboratory investigates the pathogenic mechanisms of cytokines in inflammatory and musculoskeletal conditions such as rheumatoid arthritis, osteolysis and orthopaedic implant loosening/failure, and systemic lupus erythematosus. He is interested in how cytokines and ...
Read More

Koretzky

Gary Koretzky

Our work has focused on the molecular events important for immune cell development and function with a particular interest in the signaling events initiated by surface receptor engagement. We have been particularly interested in ...
Read More

Dupnik

Kate Dupnik

My long-term goal as a physician-scientist is to explore differential human immune responses to mycobacterial pathogens, including Mycobacterium tuberculosis and M. leprae.

Guo

CJ Guo

The human microbiota, including the microbes living on/in the human body, modulates host biology in multiple ways. My research aims to study the chemistry and biology behind microbe-host interactions in the context of health ...
Read More

Guzman

Monica Guzman

My primary research interest is the identification of novel therapeutic approaches for targeting leukemia stem cells (LSCs) without harming normal hematopoietic stem cells (HSCs).